296 results about "Platelet" patented technology

The invention relates to the technical field of rhinitis spray preparation, in particular to a method for preparing allergic rhinitis spray from umbilical cord mesenchymal stem cell exosomes, which comprises the following steps: 1, umbilical cord treatment; 2, culturing umbilical cord mesenchymal stem cells; 3, preparing an umbilical cord mesenchymal stem cell exosome; and 4, preparing the rhinitis spray. The rhinitis spray prepared by the method disclosed by the invention is simpler and more convenient to use. The exosome, the platelet growth factor and other substances in the rhinitis spray well solve the core problems of single curative effect, large side effect, low compliance and the like in the traditional rhinitis treatment, and through the induction and repair functions of the stem cell exosome and the bactericidal ability of the antibacterial peptide, the nasal cavity environment is improved, the anaphylactic reaction is reduced, the nasal mucosa is repaired, and the rhinitis treatment effect is improved. The allergic rhinitis is expected to be fundamentally treated.

The invention discloses a platelet growth factor derived polypeptide as well as a composition and application thereof. The amino acid sequence of the polypeptide is shown as Seq ID No: 1 (RP1601: LLKLLKKLLKKLLKK). KKIIKKL is used as a core active sequence, a variant library is designed by adopting a special design rule (AABB cycle rule), optimization is carried out by combining a polypeptide activity prediction system with a molecular docking technology, finally five candidate polypeptides are screened out, the polypeptide RP1601 has a better balance expression between drug effect and safety, and the polypeptide RP1601 is simple in structure, easy to synthesize and optimize and high in stability, and can be used for preparing a polypeptide RP1601. Therefore, the polypeptide is determined as an optimal candidate polypeptide; based on excellent anti-inflammatory, repair-promoting and anti-oxidation characteristics of the polypeptide, the invention further provides application of the polypeptide in cosmetics and medicines.

The invention belongs to the technical field of pharmaceutical preparations. The invention discloses a multifunctional bionic nano preparation, a preparation method and application. According to the multifunctional bionic nano preparation, the ginsenoside Rg3 has the dual functions of a medicine and a membrane stabilizer, the platelet membrane has the natural targeting capability on circulating tumor cells and metastases, and meanwhile, the cationic liposome is used for adsorbing negatively-charged NETs nucleic acid protein compounds, so that potential reversal and active targeting are achieved, and the multifunctional bionic nano preparation has a good application prospect. And by co-carrying paclitaxel (PTX) and a photothermal agent (PCP) and integrating photothermal-chemotherapy-immunogenic death (ICD) induction functions, the tumor-related fibroblast activation can be effectively inhibited, circulating tumor cells can be efficiently captured, a tumor immune microenvironment can be remodeled, the tumor cells can be effectively killed, and tumor distal metastasis can be inhibited.

The invention relates to an extraction and culture method of urine-derived stem cells, and belongs to the field of cell biology and regenerative medicine. The method comprises the following steps: coating a culture plate with a gelatin solution; collecting clean midstream urine of healthy people and adding antibiotics; centrifugally separating the cell precipitate; washing with a phosphate buffer solution; re-suspending the precipitate by using a urine stem cell complete culture medium for primary culture; and after the cells grow to a certain fusion degree, carrying out passage amplification. The urine stem cell complete medium comprises a basic medium, fetal calf serum, epidermal growth factors, platelet-derived growth factors and basic fibroblast growth factors. By adopting the method disclosed by the invention, the urine-derived stem cells can be efficiently and stably separated from urine, and the obtained cells have high multiplication capacity, good stemness maintaining capacity, multidirectional differentiation potential and immunoregulation function, and can provide an ideal seed cell source for treating diseases such as diabetic erectile dysfunction.

The present disclosure relates to methods of reducing the risk of thrombosis with thrombocytopenia syndrome (TTS) associated with adenoviral vector therapy.

The application discloses an evaluation method for predicting the safety of EGFR TKIs monotherapy for NSCLC. The method comprises the following steps: obtaining the data of a plurality of patients receiving EGFR TKIs treatment; taking MDRAE (maximum grade of drug-related adverse event) as a safety index, constructing a safety evaluation final model, and the final model is an ordered logistic regression model, the covariates of the final model include normalized steady-state trough concentration, EGFR TKIs treatment history, gender, baseline glutamyltransferase, baseline uric acid, baseline creatine kinase, baseline platelets and baseline lymphocytes; obtaining the data of a target patient, inputting the numerical values of each covariate in the data of the target patient into the final model; determining the first probability of MDRAE of the target patient being grade 3 and above, the second probability of MDRAE being grade 2 and the third probability of MDRAE being grade 1 and below according to the final model, and taking the grade corresponding to the maximum probability in the three probabilities as the predicted grade of MDRAE of the target patient. The application improves the accuracy of predicting the safety of EGFR TKIs monotherapy for NSCLC.

The invention belongs to the technical field of biological medicine, and provides an antibody targeting Gn glycoprotein on the surface of a severe fever with thrombocytopenia syndrome virus and application of the antibody. The antibodies N2C1 and N2D2 and the bispecific antibody obtained by modification based on the antibodies N2C1 and N2D2 provided by the invention can be specifically combined with Gn glycoprotein on the surface of the severe fever with thrombocytopenia syndrome virus, and show a strong neutralization protection effect in in-vitro cell and in-vivo animal experiments. Therefore, the N2C1 and N2D2 antibodies and the bispecific antibody obtained by modification can be used as drugs for preventing or treating severe fever with thrombocytopenia syndrome virus infection.

In one aspect, the invention provides compositions and methods for preventing, reducing, and / or treating a disease, disorder or condition associated with fibrin-induced activation of the complement system and the associated activation of the coagulation and / or contact systems comprising administering a therapeutic amount of a MASP-2 inhibitory antibody to a subject in need thereof. In some embodiments, the methods of the invention provide anticoagulation and / or antithrombosis and / or antithrombogenesis without affecting hemostasis. In one embodiment of this aspect of the invention, the compositions and methods are useful for treating a subject is suffering from, or at risk of developing, a disease, disorder or condition associated with complement-related inflammation, excessive coagulation or contact system activation initiated by fibrin or activated platelets.

The invention discloses a lipid nanoparticle-platelet conjugate as well as a preparation method and application thereof. The conjugate is formed by coupling lipid nanoparticles and platelets through a covalent modification method, a non-covalent modification method or a genetic engineering method, and the lipid nanoparticles can be loaded with nucleic acid, small molecules, protein / polypeptide drugs or CRISPR / Cas system components. The lipid nanoparticles have the drug carrying function of lipid nanoparticles and the natural spleen targeting characteristic of platelets, and the drug uptake rate and delivery efficiency of immune cells can be improved. The preparation method adopts manual mixing, ethanol injection or a microfluidic method, is simple, convenient and efficient, can be completed within several minutes, and does not damage platelets. According to the conjugate, the drug loading type and the coupling mode can be adjusted according to different diseases, the limitation of a single drug carrier is broken through, and the conjugate can adapt to various scenes such as tumor treatment and vaccine delivery and meet the personalized treatment requirement.

The present disclosure relates to a use of Herombopag or a pharmaceutically acceptable salt thereof in treatment of tumor chemotherapy-induced thrombocytopenia. Specifically, the present disclosure relates to a disease treatment method, comprising: administering to a patient Herombopag or a pharmaceutically acceptable salt thereof, which can significantly increase the blood platelet count of a subject.

The present application relates to the application of Bifidobacterium longum subsp.longum BL21 in the preparation of a preparation for improving hematopoietic dysfunction, wherein the Bifidobacterium longum subsp.longum BL21 is a Bifidobacterium longum subsp.longum BL21 strain with a preservation number of CGMCC No.10452.The present application develops a new microbial strategy for improving hematopoietic dysfunction, and uses the Bifidobacterium longum subsp.longum BL21 in the preparation of a preparation for improving hematopoietic dysfunction.It is found that the Bifidobacterium longum subsp.longum BL21 can increase the number of peripheral blood cells (red blood cells and white blood cells), the content of platelets or the content of hemoglobin, reverse the weight loss caused by hematopoietic dysfunction, and improve the serum inflammatory response and the spleen inflammatory response caused by hematopoietic dysfunction.The present application also provides a new idea for the wide application of the Bifidobacterium longum subsp.longum BL21.

This invention belongs to the field of animal model construction technology, specifically relating to a mouse immunosuppressive model that maintains a long-term immunosuppressive state, its construction method, and its application. This invention establishes a stable immunosuppressive state model with reduced neutrophil count and no significant decrease in erythrocyte count by administering different doses of immunosuppressants (10-50 mg / kg body weight) to Balb / c mice via a combination of "reduced total dose + multiple gavage administration + satellite monitoring." The method for constructing this mouse immunosuppressive model reduces drug usage, controls neutrophil count rebound, establishes a stable model of reduced neutrophil count, and avoids deep bone marrow suppression (i.e., does not cause an uncontrollable decrease in erythrocyte or platelet count), which is beneficial for long-term experimental conduct and drug evaluation.

The application discloses a nitrogen acetylated carbazole alkaloid, and the structure is selected from one of the following structures: The application discloses a nitrogen acetylated carbazole alkaloid produced by fermentation of streptomyces J1074, and provides a biosynthetic preparation method, which is more green and environmental protection, and cost reduction compared with a chemical synthesis method; the compound ATC-A provided by the application shows significant antithrombotic activity in a thrombotic zebrafish model, which may be related to down-regulation of gene expression related to platelet activation and blood coagulation cascade, and has important development prospect and clinical application value.

The present invention relates to a microfluidic device and a method for separating plasma from a blood sample, and to the use of same. The device allows the processing of millimetric blood samples, improved plasma extraction, and the extraction of platelet-enriched high-purity plasma with a low content of activated platelets.

The invention discloses a serum substitute compatible umbilical cord mesenchymal stem cell culture medium additive composition and application thereof. The serum substitute compatible umbilical cord mesenchymal stem cell culture medium additive composition is prepared from the following components in parts by mass: 15 to 25 parts of platelet-derived growth factor-BB; 15 to 25 parts of basic fibroblast growth factors; 8 to 12 parts of transforming growth factor-beta; and 8-12 parts of recombinant human insulin. The serum substitute compatible umbilical cord mesenchymal stem cell culture medium additive composition and the application thereof disclosed by the invention have the following beneficial effects: (1) the proliferation efficiency is remarkably improved; (2) the cell morphology and dryness can be well maintained; and (3) the compliance and the compatibility are good.

The invention relates to the technical field of medical artificial intelligence monitoring, and discloses an intelligent monitoring method and system for a perfusion curative effect of a thin endometrial rich microplate. The method comprises the following steps: standardizing and fusing multi-source monitoring data, constructing a derivative feature set reflecting a treatment coordination rule through cross-cycle feature derivation, and establishing a curative effect behavior coding library according to the derivative feature set. After the real-time data is subjected to standardization processing, frame-by-frame mode matching and similarity calculation are carried out on the real-time data and a coding library, a corresponding analysis path is activated according to a result, and a curative effect behavior fragment with a timestamp is generated. The segments are associated and aggregated to form a complete curative effect event chain, key turning points are marked, and finally a structured monitoring report and a decision signal are generated through multi-dimensional influence evaluation. According to the invention, the conversion from static parameter judgment to dynamic curative effect behavior intelligent analysis is realized, and the continuity, accuracy and early warning capability of treatment process monitoring are improved.

This invention discloses the application of platelet-reactive protein-4 (THBS4) in the diagnosis and treatment of endometriosis. Through bioinformatics integration analysis, clinical sample validation, and in vitro and in vivo experiments, this invention confirms that THBS4 is significantly highly expressed in both ectopic lesions and peripheral blood of patients with endometriosis, and its expression level is positively correlated with disease severity. The area under the receiver operating characteristic (AUC) curve for THBS4 alone in diagnosing endometriosis is 0.930, significantly superior to cancer antigen 125 (CA125); the AUC for the combined diagnosis of THBS4 and CA125 reaches 0.968. Simultaneously, silencing the THBS4 gene effectively inhibits the proliferation, migration, and invasion of human endometrial stromal cells, and significantly reduces the volume and fibrosis area of ​​ectopic lesions in a mouse model of endometriosis. This invention provides a highly sensitive and specific new biomarker for the non-invasive or minimally invasive early diagnosis of endometriosis, and provides new targets and candidate drugs for non-hormone-dependent targeted therapy.

A method for collecting blood components, comprising: separating a first amount of plasma from whole blood; separating a total amount of collectable platelets from whole blood available after separating the first amount of plasma; if the total collection amount after the separation of the total amount of platelets is less than a maximum value adjusted by real-time data related to collection, then separating a second amount of plasma from the whole blood available after the separation of the total amount of platelets, and then separating a total amount of erythrocytes from the whole blood available after the separation of the second amount of plasma; and if the total collection amount is at a maximum adjusted by the real-time data relating to the collection, separating a total amount of red blood cells from the whole blood available after separating the total amount of platelets.

The present application belongs to the field of biomedical technology, and particularly relates to an axial length and growth trend evaluation method of eye axis based on PDGFRA gene and a PDGFRA enzyme activity control agent. The method comprises the following steps: 1) collecting an eye biological sample of a subject; 2) based on the expression level of PDGFRA gene of platelet-derived growth factor receptor alpha in the collected biological sample; 3) based on the expression level, calculating the axial length of the eye axis according to the quantitative relationship between the expression amount of PDGFRA and the axial length of the eye axis, and predicting the growth trend of the axial length of the eye axis through additional calculation. The technical scheme of the present application can effectively detect and evaluate the axial length of the eye axis, effectively judge the growth trend of the axial length of the eye axis, and directly and efficiently control the axial length of the eye axis and its growth trend through the existing drug components.

A method for the expression and / or for the amplification of the expression of thrombospondin-1, fibronectin, vimentin and / or mimecan in human skin. the method comprises applying to human skin at least one caviar extract which is capable of causing the expression and / or the amplification of the expression of thrombospondin-1, fibronectin, vimentin and / or mimecan in human skin.

Disclosed are compounds that are parathyroid hormone receptor 1 agonists, and methods useful for preventing or treating osteoporosis, fracture, osteomalacia, arthritis, thrombocytopenia, hypoparathyroidism, hyperphosphatemia or tumoral calcinosis.

The present application relates to the technical field of disease detection, and more particularly to a method for diagnosing and treating early atherosclerotic plaques based on multifunctional nanomaterial CeOx-P@PM, which comprises the following steps: S1: assembling CeOx with a MMP2 specific probe to form a CeOx-P compound; and S2: coating the CeOx-P compound with a biomimetic platelet membrane as a carrier to assemble CeOx-P@PM nanoparticles. The method for diagnosing and treating early atherosclerotic plaques based on multifunctional nanomaterial CeOx-P@PM has the excellent characteristics of efficient ROS removal, high bioavailability, lesion targeting, and dual-mode precise imaging, and will provide great help for the diagnosis and treatment of early atherosclerotic plaques in clinical practice.

The invention relates to a gastric cancer evaluation system based on a platelet subcellular structure, comprising: a data acquisition module for acquiring a carcino-embryonic antigen level in a blood sample of a detected subject and a platelet proportion in which alpha particles are regularly distributed; the data analysis and judgment module is used for jointly calculating the risk score of the subject suffering from the gastric cancer according to the platelet proportion of'regular distribution 'of alpha particles and the carcino-embryonic antigen level; and the result output module is used for outputting a corresponding gastric cancer assessment result according to the risk score. According to the platelet proportion of'regular distribution 'of alpha particles in a blood sample of a subject and the carcino-embryonic antigen level, the risk score of the subject suffering from the gastric cancer is jointly calculated, the risk of the subject suffering from the gastric cancer is judged, the specificity is 87.5%, and the sensitivity is 87.5%.

The invention provides a mesenchymal stem cell medicine for promoting knee joint cartilage regeneration as well as a preparation method and application thereof, and belongs to the technical field of medicines. The preparation method comprises the following steps: reacting polyethyleneimine with linoleoyl chloride to prepare linoleoyl chloride modified polyethyleneimine for preparing curcumin lipidosome, and reacting with multifunctional peptide to prepare multifunctional lipidosome; the mesenchymal stem cells are mixed with self-assembled RADA16 polypeptide embedded with TGF-beta1 and BMP-6 and subcultured mesenchymal stem cells, the mixture is added into autologous platelet-enriched plasma, and the mesenchymal stem cell medicine for promoting knee joint cartilage regeneration is prepared. According to the invention, curcumin is embedded by lipidosome, mesenchymal stem cells can promote osteogenesis differentiation by using provided nutrients, and interference of inflammatory microenvironment is effectively prevented. Meanwhile, the self-assembled RADA16 polypeptide wraps TGF-beta1 and BMP-6, the synergistic effect is beneficial to regeneration and repair of cartilage tissue, proliferation of bone cells is promoted, and cartilage repair and regeneration are facilitated.

The invention discloses a platelet increasing capsule characteristic chromatogram and a construction method and application thereof, and belongs to the technical field of quality control of traditional Chinese medicine compound preparations. According to the method, 13 control components including gallic acid, catechin, paeoniflorin, forsythiaside B, benzoic acid, astragalus smicus glycoside, forsythin, arctiin, liquiritigenin, benzoyl paeoniflorin, paeonol, arctigenin and indirubin are selected, a high performance liquid chromatography-mass spectrometry technology is applied, multiple batches of preparation samples are analyzed, and the content of the components in the preparation samples is determined. And establishing a characteristic spectrum of the chemical components. Compared with a traditional method, the technology has good precision and reproducibility, the data result is accurate and reliable, meanwhile, the technology can identify the 13 components at the same time under the same chromatographic condition, the analysis efficiency is remarkably improved, synchronous monitoring of multiple effective components is achieved, and the consistency and stability of the preparation quality can be guaranteed.

This application relates to the fields of biomedicine and wound repair technology, and particularly to the application of platelet exosomes in the treatment of diabetic wound healing. This application discloses the use of platelet exosomes in the preparation of products having one or more of the following functions: 1) prevention and / or treatment of diabetic foot; 2) promotion of wound healing and / or tissue repair; 3) shortening wound healing time; 4) promoting granulation tissue growth; 5) enhancing wound angiogenesis; 6) alleviating inflammatory responses; 7) inhibiting the expression of pro-inflammatory factors; 8) promoting the expression of anti-inflammatory factors; 9) reducing MMP-9 expression; and 10) increasing MMP-2 expression. It is particularly suitable for the treatment of diabetic foot ulcers, delayed wound healing, and related complications, and also covers the use of this product in the preparation of diabetic foot treatment drugs and medical dressings.

The application provides a stem cell collector, which comprises a body and two extrusion devices, the body has two inner cavities, a front side wall of the body is formed with two extrusion surfaces, the extrusion surfaces are provided with openings in communication with the inner cavities, and the two extrusion devices are arranged on the body and correspond to one extrusion surface respectively. The extrusion device comprises an extrusion plate, a first moving assembly, a partition plate, a second moving assembly, an extrusion block, a third moving assembly and a driving mechanism. The stem cell collector can automatically extrude a blood bag, facilitates the collection of a solution containing a plasma layer, a white blood cell and platelet layer and a small part of a red blood cell layer, reduces the mixing of the red blood cell layer, improves the collection efficiency and brings convenience for the collection of stem cells.

A subject can be treated for cardiogenic shock and / or sepsis, or their symptoms using platelet-derived extracellular vesicles (PEVs) or mitlets that include PEVS. The PEVs include mitochondria. The PEVs can be collected by obtaining blood from one or more donors, adding an anticoagulant and a buffer to the blood to form a mix, separating the mix into supernatant and platelet rich plasma (PRP), collecting the PRP and stimulating the collected PRP, thereby expelling extracellular vesicles from platelets in the PRP, and collecting the extracellular vesicles as the PEVs. PEVs can also be isolated from source cells grown in a bioreactor and suspended in a buffer to preserve the PEVs.

Disclosed herein are nucleic acid constructs that can be used to build genetic circuits for producing antibodies comprising split toxins. Also disclosed herein are methods of producing platelets comprising the antibodies. The platelets produced by the methods disclosed herein can be used to target circulating tumor cells.

The present invention provides a method for determining the quality of cultured corneal endothelial cells (CECs) comprising measuring in or on a cultured CEC a level of expression of the genes Thrombospondin-2 (THBS2) and / or Vitelline Membrane Outer Layer 1 Homolog (VMO1), and determining that the quality of said cultured CEC is non-therapy-grade if said measured level of expression corresponds to a THBS2+ and / or VMO1+ expression profile.